News Releases
SUNNYVALE, Calif., April 26, 2012 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following investor conferences, and invited investors to participate via webcast.
|
|
Deutsche Bank Health Care Conference, Boston, MA |
|
|
Wednesday, May 9, 2012 at 10.00 a.m. Eastern Time |
|
|
|
|
|
Baird Growth Conference, Chicago, IL |
|
|
Thursday, May 10, 2012 at 9.30 a.m. Central Time |
|
|
|
|
|
Bank of America Merrill Lynch Healthcare Conference, Las Vegas, NV |
|
|
Thursday, May 17, 2012 at 9.20 a.m. Pacific Time |
|
|
|
|
|
Jefferies Global Healthcare Conference, New York, NY |
|
|
Tuesday, June 5, 2012 at 10.30 a.m. Eastern Time |
|
|
|
|
|
Goldman Sachs Healthcare Conference, Rancho Palos Verdes, CA |
|
|
Wednesday, June 6, 2012 at 10.40 a.m. Pacific Time |
|
|
|
|
|
William Blair Growth Conference, Chicago, IL |
|
|
Tuesday, June 12, 2012 at 11.30 a.m. Central Time |
Accessing Live Webcasts
To access the live webcasts for these events, please visit Cepheid's website at www.cepheid.com/investors at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software. A replay of the webcasts will be available shortly following the presentation and will remain available for at least 90 days.
About Cepheid
Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy to use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to access the full power of molecular diagnostics. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit www.cepheid.com.
|
|
CONTACTS: |
|
|
|
|
For Media Inquiries: |
For Investor Inquiries: |
|
|
|
|
|
|
|
|
Jared Tipton Cepheid Corporate Communications Tel: (408) 400-8377 communications@cepheid.com |
Jacquie Ross Cepheid Investor Relations Tel: (408) 400-8329 investor.relations@cepheid.com |
|
SOURCE Cepheid
